These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 27743888)

  • 1. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
    J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?
    Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB
    Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
    Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
    Ladbury CJ; Rusthoven CG; Camidge DR; Kavanagh BD; Nath SK
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):346-355. PubMed ID: 31175902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
    Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
    Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
    Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.
    Eaton BR; Pugh SL; Bradley JD; Masters G; Kavadi VS; Narayan S; Nedzi L; Robinson C; Wynn RB; Koprowski C; Johnson DW; Meng J; Curran WJ
    J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27206636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
    Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
    Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
    Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
    Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
    McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
    Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
    Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.
    Grant JD; Sobremonte A; Hillebrandt E; Allen PK; Gomez DR
    Radiat Oncol; 2015 Jan; 10():32. PubMed ID: 25636372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Radiation Doses to the Heart on Survival for Stereotactic Ablative Radiotherapy for Early-stage Non-Small-cell Lung Cancer: An Artificial Neural Network Approach.
    Chan ST; Ruan D; Shaverdian N; Raghavan G; Cao M; Lee P
    Clin Lung Cancer; 2020 Mar; 21(2):136-144.e1. PubMed ID: 31932217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
    Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.